Eucomed responds over EU's hTEPS (human tissue engineered products) U-turn:
This article was originally published in Clinica
Executive Summary
Eucomed, the European medical device industry association, can accept that the overall regulatory framework for human tissue engineered products (hTEPs) is linked to the EU pharmaceutical legislation for the sake of speedy regulation. However, steps taken to ensure that any modifications to the Regulation on Medicinal Products for Human Use will appropriately take into account that hTEPs are NOT medicinal products. This is the official response of Eucomed, released as Clinica went to press, to the European Commission's proposal for a community Regulatory Framework on Advanced Therapies, the deadline for which was originally June 20, but was ultimately extended by one week. Clinica will cover more Eucomed detailed comments in issue No 1164.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.